Effectiveness of Paxlovid in reducing severe coronavirus disease 2019 and mortality in high-risk patients
R Najjar-Debbiny, N Gronich, G Weber… - Clinical Infectious …, 2023 - academic.oup.com
Background Paxlovid was granted an Emergency Use Authorization for the treatment of mild
to moderate coronavirus disease 2019 (COVID-19), based on the interim analysis of the …
to moderate coronavirus disease 2019 (COVID-19), based on the interim analysis of the …
Effectiveness of Paxlovid in Reducing Severe Coronavirus Disease 2019 and Mortality in High-Risk Patients.
R Najjar-Debbiny, N Gronich, G Weber… - Clinical Infectious …, 2023 - search.ebscohost.com
Background Paxlovid was granted an Emergency Use Authorization for the treatment of mild
to moderate coronavirus disease 2019 (COVID-19), based on the interim analysis of the …
to moderate coronavirus disease 2019 (COVID-19), based on the interim analysis of the …
Effectiveness of Paxlovid in Reducing Severe Coronavirus Disease 2019 and Mortality in High-Risk Patients
R Najjar-Debbiny, N Gronich, G Weber… - Clinical Infectious …, 2023 - academic.oup.com
Background Paxlovid was granted an Emergency Use Authorization for the treatment of mild
to moderate coronavirus disease 2019 (COVID-19), based on the interim analysis of the …
to moderate coronavirus disease 2019 (COVID-19), based on the interim analysis of the …
Effectiveness of Paxlovid in Reducing Severe Coronavirus Disease 2019 and Mortality in High-Risk Patients
R Najjar-Debbiny, N Gronich, G Weber… - Clinical Infectious …, 2022 - cir.nii.ac.jp
抄録< jats: title> Abstract</jats: title>< jats: sec>< jats: title> Background</jats: title>< jats: p>
Paxlovid was granted an Emergency Use Authorization for the treatment of mild to moderate …
Paxlovid was granted an Emergency Use Authorization for the treatment of mild to moderate …
[PDF][PDF] Effectiveness of Paxlovid in Reducing Severe Coronavirus Disease 2019 and Mortality in High-Risk Patients
R Najjar-Debbiny, N Gronich, G Weber… - 2022 - ima-associations.s3.amazonaws …
Background. Paxlovid was granted an Emergency Use Authorization for the treatment of
mild to moderate coronavirus disease 2019 (COVID-19), based on the interim analysis of the …
mild to moderate coronavirus disease 2019 (COVID-19), based on the interim analysis of the …
[PDF][PDF] Effectiveness of Paxlovid in Reducing Severe Coronavirus Disease 2019 and Mortality in High-Risk Patients
R Najjar-Debbiny, N Gronich, G Weber, J Khoury… - 2022 - natap.org
Background. Paxlovid was granted an Emergency Use Authorization for the treatment of
mild to moderate coronavirus disease 2019 (COVID-19), based on the interim analysis of the …
mild to moderate coronavirus disease 2019 (COVID-19), based on the interim analysis of the …
Effectiveness of paxlovid in reducing severe coronavirus disease 2019 and mortality in high-risk patients.
R Najjar-Debbiny, N Gronich, G Weber, J Khoury… - 2022 - cabidigitallibrary.org
Background: Paxlovid was granted an Emergency Use Authorization for the treatment of
mild to moderate coronavirus disease 2019 (COVID-19), based on the interim analysis of the …
mild to moderate coronavirus disease 2019 (COVID-19), based on the interim analysis of the …
[PDF][PDF] Effectiveness of Paxlovid in Reducing Severe COVID-19 and Mortality in High Risk Patients
R Najjar-Debbiny - 2022 - researchgate.net
1 Effectiveness of Paxlovid in Reducing Severe COVID-19 and Mortality in High Risk
Patients 1 2 Ronza Najjar-Debbiny, MD1,2*, Na Page 1 © The Author(s) 2022. Published by …
Patients 1 2 Ronza Najjar-Debbiny, MD1,2*, Na Page 1 © The Author(s) 2022. Published by …
Effectiveness of Paxlovid in Reducing Severe Coronavirus Disease 2019 and Mortality in High-Risk Patients.
R Najjar-Debbiny, N Gronich, G Weber… - … Diseases: an Official …, 2023 - europepmc.org
Background Paxlovid was granted an Emergency Use Authorization for the treatment of mild
to moderate coronavirus disease 2019 (COVID-19), based on the interim analysis of the …
to moderate coronavirus disease 2019 (COVID-19), based on the interim analysis of the …
Effectiveness of Paxlovid in Reducing Severe Coronavirus Disease 2019 and Mortality in High-Risk Patients
R Najjar-Debbiny, N Gronich… - … publication of the …, 2023 - pubmed.ncbi.nlm.nih.gov
Background Paxlovid was granted an Emergency Use Authorization for the treatment of mild
to moderate coronavirus disease 2019 (COVID-19), based on the interim analysis of the …
to moderate coronavirus disease 2019 (COVID-19), based on the interim analysis of the …